Orbis Medicines is a leader in oral macrocycle drug discovery. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties defined by the presence of a cyclic structure. The company's portfolio of next-generation macrocycle drugs called ‘nCycles’ are systematically designed by Orbis’ nGen platform to be orally bioavailable and membrane permeable, solving decades-long challenges in macrocycle drug design.
Total raised: $28.22M
Investors 1
| Date | Name | Website |
| 05.03.2024 | Forbion | forbion.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.03.2024 | Seed | $28.22M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 04.03.2024 | Orbis Medicines: Oral Macrocycle Drug Discovery Company Rais... | Orbis Medicines – a leader in oral macrocycle drug discovery – announced its launch with a €26 milli... | pulse2.com... |
| 01.03.2024 | Orbis Medicines Revolutionizing Oral Macrocycle Drug Discove... | Orbis Medicines, a biotech company based in Copenhagen, Denmark, is making waves in the world of dru... | parsers.vc... |
| 29.02.2024 | Startup Orbis Medicines Launches With €26M for Next-Generati... | For all of the benefit that biologic drugs provide as treatments for chronic conditions, these medic... | medcitynew... |
| 29.02.2024 | Orbis Medicines Launches with €26M Seed Financing | Orbis Medicines, a Copenhagen, Denmark-based company which specializes in oral macrocycle drug disco... | finsmes.co... |
| - | Orbis Medicines | “Orbis Medicines” | fastfounde... |